Lucid Diagnostics (LUCD) revenue and earnings history
Lucid Diagnostics reported revenue of $4.71M for fiscal 2025 (year ended Dec 31, 2025), +8.3% on the year before, and net income of −$58M.
Over 4 years, from fiscal 2021 to fiscal 2025, revenue grew at a compound rate of +75.2% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $4.71M+8.3% | −$49.6M | −$58M | −$46.5M | $197K | −$46.7M | $4.49M | — | — | — | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Lucid Diagnostics (LUCD) on OQRO.
Common questions
What was Lucid Diagnostics's revenue in fiscal 2025?
$4.71M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 25, 2026. That is +8.3% on fiscal 2024 ($4.35M).
How fast has Lucid Diagnostics's revenue grown?
From $500K in fiscal 2021 to $4.71M in fiscal 2025: a compound annual growth rate of +75.2% over 4 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Lucid Diagnostics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Lucid Diagnostics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
